Navigation Links
TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
Date:10/13/2009

TAXIS Pharmaceuticals, Inc. (TAXIS), Rutgers, The State University of New Jersey, and the University of Medicine and Dentistry of New Jersey (UMDNJ) have entered into an exclusive licensing agreement for worldwide rights to develop and commercialize a novel antimicrobial technology addressing multidrug-resistant (MDR) bacterial infections. The alarming rise in the number of multidrug-resistant (MDR) bacterial pathogens that have emerged and spread in recent years has dramatically reduced the utility of the current arsenal of antibiotics. Two such MDR pathogens in particular have been recognized as major threats to global public health, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). TAXIS is in the process of identifying and validating lead drug candidates that target MRSA and VRE with efficacies that are superior to current standards of therapeutic care.

"The compounds under investigation have great potential to treat a broad-spectrum of emerging, drug-resistant pathogens that represent large and growing public health and biodefense threats", said Gregory Mario, TAXIS' Chief Executive Officer. "We are excited to develop these further and move them closer to the clinic." The novel antimicrobial technology was discovered at the universities by Professors Daniel S. Pilch, Ph.D. (Department of Pharmacology, UMDNJ-Robert Wood Johnson Medical School) and Edmond J. LaVoie, Ph.D. (Department of Medicinal Chemistry, Rutgers University-Ernest Mario School of Pharmacy).


'/>"/>

Contact: Gregory G. Mario
GMario@TAXISPharma.com
609-240-8463
Rutgers University
Source:Eurekalert

Page: 1

Related biology news :

1. InVivo and CEVEC pharmaceuticals sign license agreement regarding the use of human CAP-T Technology for production of recombinant proteins
2. Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference
3. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
4. NMR researchers unlock hydrogens secrets to spot polymorphism in pharmaceuticals
5. Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases
6. Bacteria from sponges make new pharmaceuticals
7. MSU licenses plant oil enhancement technology to BASF Plant Science
8. UGA licenses technology to make fuel from dead forests and agricultural waste
9. UGA licenses new Bermuda grass that thrives in sun and shade
10. UGA licenses invention that kills food-borne pathogens in minutes
11. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Feb. 22, 2017 With the biometrics ... Research identifies four technologies that innovative and agile ... significant share in the changing competitive landscape: multifactor ... authentication.   "Companies can no longer ... security," says Dimitrios Pavlakis , Industry Analyst ...
(Date:2/16/2017)... Feb. 16, 2017  Genos, a community for ... it has received Laboratory Accreditation from the College ... presented to laboratories that meet stringent requirements around ... rigorous processes. "Genos is committed to ... practices. We,re honored to be receiving CAP accreditation," ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... BEIJING, Feb. 23, 2017 China Biologic Products, Inc. ... integrated plasma-based biopharmaceutical company in China, today announced its financial ... Fourth Quarter 2016 Financial Highlights ... increased by 21.7% in RMB terms, or increased by 13.6% ... the same quarter of 2015. Gross profit ...
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook Labs is ... include an array of biochemical analyses critical for Lead Discovery. The company’s ... and SAR programs, including inhibitor potency and selectivity, mechanism of action, and inhibitor ...
(Date:2/23/2017)... Feb. 23, 2017  Imanis Life Sciences announced ... of oncolytic vaccinia viruses for virotherapy research. These ... of Genelux,s proprietary, vaccinia virus-based technology platform for ... enter into a partnership with Genelux to offer ... viruses for use in research," said Dr. ...
(Date:2/23/2017)... ... 23, 2017 , ... The Greater Gift Initiative, Inc , (GGI) a ... Research . GGI's mission is to advance global health and highlight the greater good ... honor of each clinical trial volunteer. The vision of GGI is to serve as ...
Breaking Biology Technology: